Peri-implantitis risk factors: A prospective evaluation.


Journal

Journal of investigative and clinical dentistry
ISSN: 2041-1626
Titre abrégé: J Investig Clin Dent
Pays: Australia
ID NLM: 101524471

Informations de publication

Date de publication:
May 2019
Historique:
received: 28 02 2018
accepted: 19 11 2018
pubmed: 9 2 2019
medline: 27 11 2019
entrez: 9 2 2019
Statut: ppublish

Résumé

The aim of the present study was to create a tool to evaluate the risk of peri-implantitis according its severity. After ethics committee approval, 43 patients provided signed consent and were included prospectively. Forty-five observations were recorded. The following criteria were recorded: number of implant faces showing bleeding and/or suppuration, pocket depth on at least two faces of the implant, bone loss as a function of the length of the implant evaluated on X-rays, number of implant faces with bacterial plaque, the parameters required for determination of excess cement (screwed or sealed prosthesis, burying of sealed prostheses), periodontal status, glycemia, and annual consumption of tobacco. Each of these parameters was plotted on a chart using Microsoft Excel. Seventeen of 45 (37.8%) cases were identified as having high peri-implantitis risk, two of 45 (4.4%) had low risk, and 11 of 45 (24.4%) had moderate risk; 33.3% patients did not have peri-implantitis and were considered at very low risk. The observed results applied to the evaluation model are an effective diagnostic tool in assessing the risk of peri-implantitis. The tool takes into account parameters, which have not been taken into account until now. The information is automatically processed and allows early management of peri-implantitis.

Identifiants

pubmed: 30734522
doi: 10.1111/jicd.12398
doi:

Substances chimiques

Dental Implants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12398

Informations de copyright

© 2019 John Wiley & Sons Australia, Ltd.

Auteurs

Anthony Mazel (A)

UFR Odontologie, Aix-Marseille Université, Marseille, France.

Souad Belkacemi (S)

Aix-Marseille Université UM63, Institut de Recherche pour le Développement IRD 198, Assistance Publique - Hôpitaux de Marseille (AP-HM), Microbes, Evolution, Phylogeny and Infection (MEΦI), Institut Hospitalo-Universitaire (IHU) - Méditerranée Infection, Marseille, France.

Patrick Tavitian (P)

UFR Odontologie, Aix-Marseille Université, Marseille, France.

Grégory Stéphan (G)

UFR Odontologie, Aix-Marseille Université, Marseille, France.

Delphine Tardivo (D)

UFR Odontologie, Aix-Marseille Université, Marseille, France.

Jean Hugues Catherine (JH)

UFR Odontologie, Aix-Marseille Université, Marseille, France.

Gérard Aboudharam (G)

UFR Odontologie, Aix-Marseille Université, Marseille, France.
Aix-Marseille Université UM63, Institut de Recherche pour le Développement IRD 198, Assistance Publique - Hôpitaux de Marseille (AP-HM), Microbes, Evolution, Phylogeny and Infection (MEΦI), Institut Hospitalo-Universitaire (IHU) - Méditerranée Infection, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH